Repurposing antimalarial pyronaridine as a DNA repair inhibitor to exploit the full potential of gold-nanoparticle-mediated radiation response

dc.contributor.authorJackson, Nolan
dc.contributor.authorAlhussan, Abdulaziz
dc.contributor.authorBromma, Kyle
dc.contributor.authorJay, David
dc.contributor.authorDonnelly, James C.
dc.contributor.authorWest, Frederick G.
dc.contributor.authorLavasanifar, Afsaneh
dc.contributor.authorWeinfeld, Michael
dc.contributor.authorBeckham, Wayne
dc.contributor.authorChithrani, Devika B.
dc.date.accessioned2023-01-26T19:30:36Z
dc.date.available2023-01-26T19:30:36Z
dc.date.copyright2022en_US
dc.date.issued2022
dc.description.abstractRadiation therapy (RT) is frequently used to locally treat tumors. One of the major issues in RT is normal tissue toxicity; thus, it is necessary to limit dose escalation for enhanced local control in patients that have locally advanced tumors. Integrating radiosensitizing agents such as gold nanoparticles (GNPs) into RT has been shown to greatly increase the cure rate of solid tumors. The objective of this study was to explore the repurposing of an antimalarial drug, pyronaridine (PYD), as a DNA repair inhibitor to further enhance RT/GNP-induced DNA damage in cancerous cell lines. We were able to achieve inhibitory effects of DNA repair due to PYD at 500 nM concentration. Our results show a significant enhancement in DNA double-strand breaks of 42% in HeLa cells treated with PYD/GNP/RT in comparison to GNP/RT alone when irradiated with a dose of 2 Gy. Furthermore, there was a significant reduction in cellular proliferation for both HeLa and HCT-116 irradiated cells with the combined treatment of PYD/GNP/RT. Therefore, the emergence of promising novel concepts introduced in this study could lay the foundation for the transition of this treatment modality into clinical environments.en_US
dc.description.reviewstatusRevieweden_US
dc.description.scholarlevelFacultyen_US
dc.description.sponsorshipThis research was funded by a Nanomedicines Innovation Network (NMIN) Strategic Initiative (SI) grant, 2021-RES-SI-05; Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (DG), RGPIN-2017-04501; Kuwait Foundation for the Advancement of Sciences (KFAS), CB21-63SP-01; Canadian Institute for Health Research (CIHR), CIHR PJT-399879; and Alberta Cancer Foundation Transformative Program Project, 26603.en_US
dc.identifier.citationJackson, N., Alhussan, A., Bromma, K., Jay, D., Donnelly, J. C., West, F. G., . . . Chithrani, D. B. (2022). “Repurposing antimalarial pyronaridine as a DNA repair inhibitor to exploit the full potential of gold-nanoparticle-mediated radiation response.” Pharmaceutics, 14(12), 2795. https://doi.org/10.3390/pharmaceutics14122795en_US
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics14122795
dc.identifier.urihttp://hdl.handle.net/1828/14695
dc.language.isoenen_US
dc.publisherPharmaceuticsen_US
dc.subjectgold nanoparticlesen_US
dc.subjectpyronaridineen_US
dc.subjectcancer cellsen_US
dc.subjectradiotherapyen_US
dc.subjectDNA repairen_US
dc.subjectERCC1-XPFen_US
dc.subjectnanomedicineen_US
dc.titleRepurposing antimalarial pyronaridine as a DNA repair inhibitor to exploit the full potential of gold-nanoparticle-mediated radiation responseen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Jackson_Nolan_Pharmaceutics_2022.pdf
Size:
4.35 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2 KB
Format:
Item-specific license agreed upon to submission
Description: